Freenome

Backed by

Raised $254M in Series E on February 15, 2024 led by Roche Venture Fund.

San Francisco, United States
Series E
Remote
Healthcare
501+

Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages.

Explore Similar Companies to Freenome

Orchid

Helping couples have healthy babies.

Headlight

Online therapy and mental health services.

Silna

Make care your primary focus.

Tandem Health

Medical notes that write themselves.

Lead your health plan into the future.

Tennr

The intelligent automation platform for healthcare ops.

openevidence

The leading medical information platform.

Collate

Empowering life sciences development.